Chinmay Maheshwari

Dr. Chinmay Maheshwari

Department of Health Sciences, University of Eastern Piedmont Amedeo Avogadro, Novara, Piedmont, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
CVChiara Vidoni
Chiara Vidoni
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
Andrea EspositoAndrea Esposito
Andrea Esposito
CMChinmay Maheshwari
Chinmay Maheshwari
DDDanny N Dhanasekaran
Danny N Dhanasekaran
Ciro IsidoroCiro Isidoro
Ciro Isidoro
Chiara Vidoni, Alessandra Ferraresi, Andrea Esposito, Chinmay Maheshwari, Danny N. Dhanasekaran, Vincenzo Mollace, Ciro Isidoro. J Cancer Prev 2021;26:224-36. https://doi.org/10.15430/JCP.2021.26.4.224

Verified
Journal Article
Open access
PDF file
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
CGCarlo Girone
Carlo Girone
CMChinmay Maheshwari
Chinmay Maheshwari
LVLetizia Vallino
Letizia Vallino
DDDanny N Dhanasekaran
Danny N Dhanasekaran
Ciro IsidoroCiro Isidoro
Ciro Isidoro
One aspect of ovarian tumorigenesis which is still poorly understood is the tumor–stroma interaction, which plays a major role in chemoresistance and tumor progression. Cancer-associated fibroblasts (CAFs), the most abundant stromal cell type in the tumor microenvironment, influence tumor growth, metabolism, metastasis, and response to therapy, making them attractive targets for anti-cancer treatment. Unraveling the mechanisms involved in CAFs activation and maintenance is therefore crucial for the improvement of therapy efficacy. Here, we report that CAFs phenoconversion relies on the glucose-dependent inhibition of autophagy. We show that ovarian cancer cell-conditioning medium induces a metabolic reprogramming towards the CAF-phenotype that requires the autophagy-dependent glycolytic shift. In fact, 2-deoxy-D-glucose (2DG) strongly hampers such phenoconversion and, most importantly, induces the phenoreversion of CAFs into quiescent fibroblasts. Moreover, pharmacological inhibition (by proline) or autophagy gene knockdown (by siBECN1 or siATG7) promotes, while autophagy induction (by either 2DG or rapamycin) counteracts, the metabolic rewiring induced by the ovarian cancer cell secretome. Notably, the nutraceutical resveratrol (RV), known to inhibit glucose metabolism and to induce autophagy, promotes the phenoreversion of CAFs into normal fibroblasts even in the presence of ovarian cancer cell-conditioning medium. Overall, our data support the view of testing autophagy inducers for targeting the tumor-promoting stroma as an adjuvant strategy to improve therapy success rates, especially for tumors with a highly desmoplastic stroma, like ovarian cancer.

2 August 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
CMChinmay Maheshwari
Chinmay Maheshwari
CVChiara Vidoni
Chiara Vidoni
RTRossella Titone
Rossella Titone
ACAndrea Castiglioni
Andrea Castiglioni
CLClaudia Lora
Claudia Lora
Ciro IsidoroCiro Isidoro
Ciro Isidoro
Alternative splicing allows the synthesis of different protein variants starting from a single gene. Human Beclin 1 (BECN1) is a key autophagy regulator that acts as haploinsufficient tumor suppressor since its decreased expression correlates with tumorigenesis and poor prognosis in cancer patients. Recent studies show that BECN1 mRNA undergoes alternative splicing. Here, we report on the isolation and molecular and functional characterization of three BECN1 transcript variants (named BECN1-α, -β and -γ) in human cancer cells. In ovarian cancer NIHOVCAR3, these splicing variants were found along with the canonical wild-type. BECN1-α lacks 143 nucleotides at its C-terminus and corresponds to a variant previously described. BECN1-β and -γ lack the BCL2 homology 3 domain and other regions at their C-termini. Following overexpression in breast cancer cells MDA-MB231, we found that BECN1-α stimulates autophagy. Specifically, BECN1-α binds to Parkin and stimulates mitophagy. On the contrary, BECN1-β reduces autophagy with a dominant negative effect over the endogenous wild-type isoform. BECN1-γ maintains its ability to interact with the vacuolar protein sorting 34 and only has a slight effect on autophagy. It is possible that cancer cells utilize the alternative splicing of BECN1 for modulating autophagy and mitophagy in response to environmental stresses.

Verified
Journal Article
Open access
PDF file
CMChinmay Maheshwari
Chinmay Maheshwari
ACAndrea Castiglioni
Andrea Castiglioni
UWUthman Walusimbi
Uthman Walusimbi
CVChiara Vidoni
Chiara Vidoni
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
Ciro IsidoroCiro Isidoro
Ciro Isidoro
BECLIN-1 is a multidomain protein that, through dynamic interaction with a variety of partners, controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell fate. Although mutations in the BECN1 gene are rare in cancer, its frequent monoallelic deletion contributes to spontaneous cancer initiation by impairing autophagy, establishing it as a haploinsufficient tumor suppressor gene. The expression and activity of BECLIN-1 are further modulated by epigenetic mechanisms, alternative splicing, post-translational modifications, and alternative partner interactions. These layers of regulation critically affect the autophagy response, with an impact on cell proliferation, motility, and resistance to multiple stress stimuli. In this review article we outline the structural and functional properties of BECLIN-1 and discuss how its altered expression and protein–protein interactions can be harnessed for diagnostic and therapeutic purposes in cancer.

Verified
Journal Article
Open access
PDF file
SASalwa Amreen
Salwa Amreen
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
LVLetizia Vallino
Letizia Vallino
CMChinmay Maheshwari
Chinmay Maheshwari
RMRiccardo Moia
Riccardo Moia
Ciro IsidoroCiro Isidoro
Ciro Isidoro
Acute myeloid leukemia (AML) emerges as one of the most common and fatal leukemias. Treatment of the disease remains highly challenging owing to profound metabolic rewiring mechanisms that confer plasticity to AML cells, ultimately resulting in therapy resistance. Autophagy, a highly conserved lysosomal-driven catabolic process devoted to macromolecular turnover, displays a dichotomous role in AML by suppressing or promoting disease development and progression. Glycolytic metabolism represents a pivotal strategy for AML cells to sustain increasing energy needs related to uncontrolled growth during disease progression. In this study, we tested the hypothesis that a high glycolytic rate and low autophagy flux could represent an advantage for AML cell proliferation and thus be detrimental for patient’s prognosis, and vice versa. TCGA in silico analysis of the AML cohort shows that the high expression of MAP1LC3B (along with that of BECN1 and with low expression of p62/SQSTM1) and the high expression of BNIP3 (along with that of PRKN and of MAP1LC3B), which together are indicative of increased autophagy and mitophagy, correlate with better prognosis. On the other hand, the high expression of glycolytic markers HK2, PFKM, and PKM correlates with poor prognosis. Most importantly, the association of a low expression of glycolytic markers with a high expression of autophagy–mitophagy markers conferred the longest overall survival for AML patients. Transcriptomic analysis showed that this combined signature correlates with the downregulation of a subset of genes required for the differentiation of myeloid cells, lactate/pyruvate transporters, and cell cycle progression, in parallel with the upregulation of genes involved in autophagy/lysosomal trafficking and proteolysis, anti-tumor responses like beta-interferon production, and positive regulation of programmed cell death. Taken together, our data support the view that enhanced autophagy-mitophagy flux together with low glycolytic rate predisposes AML patients to a better clinical outcome, suggesting that autophagy inducers and glucose restrictors may hold potential as adjuvant therapeutics for improving AML management.

29 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CMChinmay Maheshwari
Chinmay Maheshwari
ACAndrea Castiglioni
Andrea Castiglioni
UWUthman Walusimbi
Uthman Walusimbi
CVChiara Vidoni
Chiara Vidoni
Alessandra FerraresiAlessandra Ferraresi
Alessandra Ferraresi
Ciro IsidoroCiro Isidoro
Ciro Isidoro
BECLIN-1 is a multidomain protein that through dynamic interaction with a variety of partners controls autophagy and apoptosis, two processes dysregulated in cancer cells, thus playing a crucial role in cell destiny. Mutations of BECN1 gene have not been described, yet its monoallelic deletion leads to insufficient autophagy with an impact on spontaneous cancer development, which identifies it as a haploinsufficient tumor suppressor gene. Epigenetic modulation of its expression, along with alternative splicing, post-translational modifications and alternative partner interactions influence its regulation of autophagy, thus affecting cancer cell behavior in terms of proliferation, motility, and survival under stress. In this review article we describe the structural and functional properties of BECLIN-1 and discuss how its altered expression and interaction with other proteins in cancer cells can be harnessed for diagnostic and therapeutic purposes.